arrow
P

Petar Pop-Damkov

AstraZeneca
H指数:9
被引数:813

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The application of mechanistic absorption, distribution, metabolism and excretion studies and physiologically-based pharmacokinetic modeling in the discovery of the next-generation oral selective estrogen receptor degrader camizestrant to achieve an acceptable human pharmacokinetic profile

基于机制性的吸收、分布、代谢和排泄研究以及生理药代动力学模型的应用,在下一代口服选择性雌激素受体降解剂camizestrant的发现中,以实现可接受的人类药代动力学特征。

2025-06-190
OA
Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase

通过口服A-T突变酶抑制剂AZD1390(醛氧化酶底物)实现人脑暴露。

2025-06-030
PRE
Discovery of (2R,4R)-4-((S)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer
2024-11-210
PRE
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2023-03-134
OA
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
2021-01-2567
OAAI
On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology (vol 97, pg 234, 2019)
2020-02-125
OAAI
On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology
2020-01-27186
OAAI